Leerink Partners Upgrades Gilead Sciences to Outperform, Raises Price Target to $96
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has upgraded Gilead Sciences from Market Perform to Outperform, raising the price target from $74 to $96.
October 21, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leerink Partners has upgraded Gilead Sciences from Market Perform to Outperform, with a new price target of $96, indicating a positive outlook for the stock.
The upgrade from Market Perform to Outperform by Leerink Partners suggests increased confidence in Gilead Sciences' future performance. The raised price target from $74 to $96 indicates expectations of significant upside potential, likely leading to positive investor sentiment and a potential increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100